secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001193125-23-056303
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 2.01, 5.02, 3.03, 4.01, 5.01, 5.03, 5.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imara completes reverse merger with Enliven; combined company to trade as ELVN
------------------------------------------------------------------------------

- Merger closed Feb 23, 2023; exchange ratio ~0.2951; ~41.1M shares outstanding post-merger.
- Former Enliven shareholders own ~84% of combined company; Imara shareholders ~16%.
- Imara shareholders receive one CVR per share for potential payments from tovinontrine sale to Cardurion.
- New leadership: Sam Kintz (CEO), Benjamin Hohl (CFO); prior Imara CEO and CFO resigned with severance.
- Auditor changed from EY to Deloitte; 1-for-4 reverse stock split; ticker changes to ELVN.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/d464771d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-056303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer